[{"id":"3ba5c955-8ec9-4668-a6f6-e10f2a3b745e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07004075","created_at":"2025-06-07T14:43:33.080Z","updated_at":"2025-06-07T14:43:33.080Z","phase":"Phase 3","brief_title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","source_id_and_acronym":"NCT07004075","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • Ivesa (firmonertinib) • Fu Mai Ning (luvometinib) • vindesine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-06-04"},{"id":"bb866355-1e34-4d35-9bb4-a41598c5e17e","acronym":"IMM1104-101","url":"https://clinicaltrials.gov/study/NCT05585320","created_at":"2022-10-18T14:57:21.622Z","updated_at":"2025-02-25T14:09:12.843Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05585320 - IMM1104-101","lead_sponsor":"Immuneering Corporation","biomarkers":" KRAS • HRAS • APC","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation","tags":["KRAS • HRAS • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"2223e62c-2304-4f09-b793-71e2fb24f5a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03224767","created_at":"2021-04-28T13:53:13.407Z","updated_at":"2025-02-25T14:15:02.976Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma","source_id_and_acronym":"NCT03224767","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CYP1A2","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-02-18"},{"id":"ab1e1b4a-5cc0-492c-9676-f254993a91a1","acronym":"ETCTN Study 10166","url":"https://clinicaltrials.gov/study/NCT03600701","created_at":"2021-01-18T17:42:08.981Z","updated_at":"2025-02-25T14:15:13.480Z","phase":"Phase 2","brief_title":"Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03600701 - ETCTN Study 10166","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • KRAS • BRAF • ALK","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["EGFR • KRAS • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/29/2018","start_date":" 11/29/2018","primary_txt":" Primary completion: 07/17/2025","primary_completion_date":" 07/17/2025","study_txt":" Completion: 07/17/2025","study_completion_date":" 07/17/2025","last_update_posted":"2025-02-17"},{"id":"eda22fa5-a154-4718-aaaf-d2fb8460e402","acronym":"","url":"https://clinicaltrials.gov/study/NCT02721459","created_at":"2021-01-18T13:18:50.231Z","updated_at":"2025-02-25T16:30:48.412Z","phase":"Phase 1","brief_title":"XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma","source_id_and_acronym":"NCT02721459","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/07/2016","start_date":" 09/07/2016","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-07"},{"id":"577a4268-ea8b-44ef-b557-7019f2e329c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691504","created_at":"2023-01-20T16:00:14.081Z","updated_at":"2025-02-25T16:46:30.558Z","phase":"Phase 1","brief_title":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","source_id_and_acronym":"NCT05691504","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • BCL2L1","pipe":"","alterations":" ","tags":["BRAF • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • pelcitoclax (APG-1252)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-05"},{"id":"858789a0-ffc7-4b5d-93c6-6eb6690616c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06553365","created_at":"2025-02-27T08:06:57.659Z","updated_at":"2025-02-27T08:06:57.659Z","phase":"Phase 2","brief_title":"Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors","source_id_and_acronym":"NCT06553365","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/15/2024","start_date":" 08/15/2024","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-08-14"},{"id":"7ee65b79-49ff-449c-ae18-0e2f8ded36d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06440850","created_at":"2024-06-08T04:18:06.782Z","updated_at":"2024-07-02T16:34:59.043Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","source_id_and_acronym":"NCT06440850","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-04"},{"id":"f89835c0-06e4-4e0a-885b-6ba816427d90","acronym":"","url":"https://clinicaltrials.gov/study/NCT03202316","created_at":"2021-01-18T15:47:27.316Z","updated_at":"2024-07-02T16:34:59.898Z","phase":"Phase 2","brief_title":"Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer","source_id_and_acronym":"NCT03202316","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Halaven (eribulin mesylate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/11/2017","start_date":" 08/11/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-31"},{"id":"2a264a2b-5ea5-4bd0-8407-7b2b5f234d25","acronym":"NACHO COBI","url":"https://clinicaltrials.gov/study/NCT04079179","created_at":"2021-01-18T19:58:29.856Z","updated_at":"2024-07-02T16:35:00.684Z","phase":"Phase 2","brief_title":"Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders","source_id_and_acronym":"NCT04079179 - NACHO COBI","lead_sponsor":"Carl Allen","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 04/19/2021","start_date":" 04/19/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-27"},{"id":"b30b1e44-f866-4d50-98ee-25a4b13b78d0","acronym":"ImmunoCobiVem","url":"https://clinicaltrials.gov/study/NCT02902029","created_at":"2021-03-22T16:53:54.040Z","updated_at":"2024-07-02T16:35:01.852Z","phase":"Phase 2","brief_title":"Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma","source_id_and_acronym":"NCT02902029 - ImmunoCobiVem","lead_sponsor":"University Hospital, Essen","biomarkers":" PD-1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-05-23"},{"id":"c6296d46-2509-4857-a66a-8bdd1dea5322","acronym":"BEAT-MBM","url":"https://clinicaltrials.gov/study/NCT03175432","created_at":"2021-01-18T15:39:32.617Z","updated_at":"2024-07-02T16:35:02.815Z","phase":"Phase 2","brief_title":"Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases","source_id_and_acronym":"NCT03175432 - BEAT-MBM","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/15/2017","start_date":" 06/15/2017","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-17"},{"id":"37f9a1df-a306-4aaa-b1f0-111ca2107f32","acronym":"","url":"https://clinicaltrials.gov/study/NCT04835805","created_at":"2021-04-08T13:52:36.101Z","updated_at":"2024-07-02T16:35:03.372Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.","source_id_and_acronym":"NCT04835805","lead_sponsor":"Genentech, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib) • belvarafenib (RG6185)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/13/2021","start_date":" 05/13/2021","primary_txt":" Primary completion: 11/28/2025","primary_completion_date":" 11/28/2025","study_txt":" Completion: 11/28/2025","study_completion_date":" 11/28/2025","last_update_posted":"2024-05-16"},{"id":"5339312c-848e-4c0d-aed2-e48d851689d4","acronym":"MORPHEUS-EC","url":"https://clinicaltrials.gov/study/NCT03281369","created_at":"2021-01-18T16:12:10.112Z","updated_at":"2024-07-02T16:35:06.566Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","source_id_and_acronym":"NCT03281369 - MORPHEUS-EC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • TIGIT","pipe":" | ","alterations":" HER-2 negative • HER-2 expression","tags":["HER-2 • PD-L1 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 10/13/2017","start_date":" 10/13/2017","primary_txt":" Primary completion: 08/24/2024","primary_completion_date":" 08/24/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-01"},{"id":"4338d698-1e9d-40b2-bf15-b2e998c85782","acronym":"Tricotel","url":"https://clinicaltrials.gov/study/NCT03625141","created_at":"2021-01-18T17:48:32.004Z","updated_at":"2024-07-02T16:35:10.102Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases","source_id_and_acronym":"NCT03625141 - Tricotel","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 06/07/2021","primary_completion_date":" 06/07/2021","study_txt":" Completion: 04/13/2023","study_completion_date":" 04/13/2023","last_update_posted":"2024-04-11"},{"id":"31d7ee1a-3f75-40a4-8d61-0c58c2bd4ffc","acronym":"NCI-2018-01399","url":"https://clinicaltrials.gov/study/NCT03108131","created_at":"2021-01-18T15:18:44.409Z","updated_at":"2024-07-02T16:35:11.100Z","phase":"Phase 2","brief_title":"Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors","source_id_and_acronym":"NCT03108131 - NCI-2018-01399","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 04/07/2017","start_date":" 04/07/2017","primary_txt":" Primary completion: 04/02/2024","primary_completion_date":" 04/02/2024","study_txt":" Completion: 04/02/2024","study_completion_date":" 04/02/2024","last_update_posted":"2024-04-05"},{"id":"baed2538-f588-4003-8b02-2b3574109f57","acronym":"","url":"https://clinicaltrials.gov/study/NCT03201458","created_at":"2021-01-18T15:47:15.387Z","updated_at":"2024-07-02T16:35:11.194Z","phase":"Phase 2","brief_title":"Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer","source_id_and_acronym":"NCT03201458","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRAF • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRAF • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 08/07/2020","primary_completion_date":" 08/07/2020","study_txt":" Completion: 02/19/2024","study_completion_date":" 02/19/2024","last_update_posted":"2024-04-05"},{"id":"567a8aef-1c29-45f6-aa4c-73624212b548","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932253","created_at":"2021-01-18T19:22:09.234Z","updated_at":"2024-07-02T16:35:12.608Z","phase":"Phase 1","brief_title":"MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)","source_id_and_acronym":"NCT03932253","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" NRAS • NF1","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Suspended","enrollment":" Enrollment 79","initiation":"Initiation: 03/21/2019","start_date":" 03/21/2019","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2024-03-27"},{"id":"5cf08ff0-036e-47fa-a6ae-ba545a8be1bd","acronym":"IMspire150","url":"https://clinicaltrials.gov/study/NCT02908672","created_at":"2021-01-17T17:17:34.789Z","updated_at":"2024-07-02T16:35:13.224Z","phase":"Phase 3","brief_title":"A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma","source_id_and_acronym":"NCT02908672 - IMspire150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 514","initiation":"Initiation: 01/13/2017","start_date":" 01/13/2017","primary_txt":" Primary completion: 10/11/2019","primary_completion_date":" 10/11/2019","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2024-03-22"},{"id":"5464bbe9-0507-491a-a174-c662a80c8226","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913037","created_at":"2023-06-22T19:11:30.805Z","updated_at":"2024-07-02T16:35:14.460Z","phase":"Phase 3","brief_title":"FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas","source_id_and_acronym":"NCT05913037","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 06/20/2023","start_date":" 06/20/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-03-15"},{"id":"b4509b46-cf96-4a36-af86-5a28202e4c9b","acronym":"CONCERTO","url":"https://clinicaltrials.gov/study/NCT04409639","created_at":"2021-01-18T21:15:48.018Z","updated_at":"2024-07-02T16:35:17.291Z","phase":"Phase 2","brief_title":"Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations","source_id_and_acronym":"NCT04409639 - CONCERTO","lead_sponsor":"University of Utah","biomarkers":" KRAS • BRAF • FLT3 • NRAS • NF1 • JAK2 • PTPN11","pipe":" | ","alterations":" BRAF mutation • NF1 mutation","tags":["KRAS • BRAF • FLT3 • NRAS • NF1 • JAK2 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2026","study_completion_date":" 08/15/2026","last_update_posted":"2024-02-28"},{"id":"b7222b36-4294-4a60-9a60-79c17a69cc40","acronym":"MEKiAUTO","url":"https://clinicaltrials.gov/study/NCT04214418","created_at":"2021-01-18T20:31:18.521Z","updated_at":"2024-07-02T16:35:17.433Z","phase":"Phase 1/2","brief_title":"Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","source_id_and_acronym":"NCT04214418 - MEKiAUTO","lead_sponsor":"Columbia University","biomarkers":" KRAS • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion","tags":["KRAS • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 02/12/2020","start_date":" 02/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-28"},{"id":"106f2d1a-d007-4d52-8a80-ced53095a782","acronym":"COTESARC","url":"https://clinicaltrials.gov/study/NCT04216953","created_at":"2021-01-18T20:31:52.644Z","updated_at":"2024-07-02T16:35:19.819Z","phase":"Phase 1/2","brief_title":"MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma","source_id_and_acronym":"NCT04216953 - COTESARC","lead_sponsor":"Centre Leon Berard","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 02/12/2020","start_date":" 02/12/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-02-12"},{"id":"2d1e326b-a843-4882-b48e-31d0ec882489","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005974","created_at":"2023-08-23T16:10:48.874Z","updated_at":"2024-07-02T16:35:20.791Z","phase":"Phase 2","brief_title":"A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation","source_id_and_acronym":"NCT06005974","lead_sponsor":"Recursion Pharmaceuticals Inc.","biomarkers":" APC • RAS • AXIN1","pipe":" | ","alterations":" APC mutation","tags":["APC • RAS • AXIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-4881"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/15/2024","start_date":" 01/15/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-06"}]